Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
<p>Abstract</p> <p>Background</p> <p>Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This rep...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-05-01
|
| Series: | BMC Neurology |
| Online Access: | http://www.biomedcentral.com/1471-2377/11/57 |